Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226793 · ClinicalTrials.gov registry record
Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 400
- Enrollment target
NCT05226793 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 400 participants.
The verdict
NCT05226793 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 400 participants
- Enrollment target
Study Summary
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxaparin doses, and results will be presented at the American Society of Health-System Pharmacists Midyear conference in December 2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2025-07-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05226793
The ClinicalTrials.gov registry entry for NCT05226793 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05226793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05226793 about?
NCT05226793 is a clinical study titled "Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients". Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be included. Collected data will be analyzed to determine the safety and effectiveness of the varying enoxa...
What is the current status of trial NCT05226793?
This trial is currently completed. The enrollment target is 400 participants. The study started on 2021-11-17. Estimated completion is 2025-07-22.
Who is sponsoring clinical trial NCT05226793?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.